CG Oncology Inc. (CGON) vs Kiniksa Pharmaceuticals International, plc (KNSA)
A side-by-side comparison of CG Oncology Inc. and Kiniksa Pharmaceuticals International, plc across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
CGON
CG Oncology Inc.
$63.64HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
KNSA
Kiniksa Pharmaceuticals International, plc
$77.09HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
Total return — CGON vs KNSA
growth of $100 · dividends reinvested · last 3yCGON +84.9% (+22.7%/yr)KNSA +315.9% (+60.8%/yr)KNSA compounded faster over this window
CGON KNSA
CGON vs KNSA: by the numbers
- •KNSA is the larger company ($5.87B vs $5.61B market cap).
- •KNSA is profitable (9.59% net margin) while CGON runs a net loss (-3602.68%).
Metrics side by side
Valuation
| Metric | CGON | KNSA |
|---|---|---|
| P/E ratio | N/A | 78.66 |
| Forward P/E | N/A | 55.35 |
| P/S ratio | 901.29 | 6.99 |
| P/B ratio | 5.45 | 8.98 |
| EV / EBITDA | N/A | 55.94 |
| FCF yield | N/A | 3.12% |
Profitability
| Metric | CGON | KNSA |
|---|---|---|
| Gross margin | -15.02% | 54.49% |
| Operating margin | -4722.13% | 11.92% |
| Net margin | -3602.68% | 9.59% |
| ROE | -21.80% | 12.33% |
| ROIC | -24.33% | 9.76% |
Growth (annualized)
| Metric | CGON | KNSA |
|---|---|---|
| Revenue CAGR (5Y) | N/A | 155.66% |
| Total return CAGR (5Y) | N/A | 47.48% |
Frequently asked
- Is CGON or KNSA more profitable?
- KNSA runs the higher net margin — CGON at -3602.68% versus KNSA at 9.59%.
Go deeper
Dig into the metrics
Kiniksa Pharmaceuticals International P/E ratioCG Oncology ROEKiniksa Pharmaceuticals International ROECG Oncology operating marginKiniksa Pharmaceuticals International operating marginCG Oncology revenue growthKiniksa Pharmaceuticals International revenue growthCG Oncology free cash flowKiniksa Pharmaceuticals International free cash flow
CG Oncology & Kiniksa Pharmaceuticals International appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.